Literature DB >> 27105393

Hypertension in children with congenital adrenal hyperplasia.

Nadia Maccabee-Ryaboy1, William Thomas2, Jennifer Kyllo3, Aida Lteif4, Anna Petryk1, Maria Teresa Gonzalez-Bolanos1, Peter C Hindmarsh5, Kyriakie Sarafoglou6.   

Abstract

OBJECTIVES: Estimates of high blood pressure (BP) incidence in children with congenital adrenal hyperplasia (CAH) vary widely; risk factors are poorly understood. We estimated incidence of hypertension by CAH subtype and sex, and assessed its association with body mass index, hydrocortisone and fludrocortisone.
DESIGN: Longitudinal. PATIENTS: Chart review of 180 paediatric CAH patients (120 salt wasting; 60 simple virilizing; 93 females) seen from 1970 to 2013. MEASUREMENTS: High BP was diagnosed by diastolic or systolic blood pressure measurement ≥95th percentile for age, sex and height; hypertension was diagnosed with high BP on at least three clinic visits.
RESULTS: Children with classic CAH who received fludrocortisone had a significantly higher rate of hypertension (55% vs 31%) than those who did not. Hypertension incidence was higher in salt-wasting CAH (58%) than in simple-virilizing CAH (35%). Hypertension first occurred before age 5 years in 91% of salt-wasting males and 50% of cases in salt-wasting females; most simple-virilizing cases occurred during ages 10-18 years. Rates of hypertension were higher in children who had three or more measurements with 17-OHP < 400 ng/dl (12·12 nmol/l), and this difference was significant in salt-wasting males. Children on fludrocortisone who had three or more readings of 17-OHP < 400 ng/dl (12·12 nmol/l) had a significantly higher rate of hypertension than those who did not. Hydrocortisone dose was not associated with hypertension.
CONCLUSION: Children with CAH are at higher risk for hypertension than the general paediatric population, and incidence differs by sex and CAH subtype. Hypertension was higher in children on fludrocortisone and who were oversuppressed.
© 2016 John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27105393     DOI: 10.1111/cen.13086

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  14 in total

1.  Obesity in children with congenital adrenal hyperplasia in the Minnesota cohort: importance of adjusting body mass index for height-age.

Authors:  Kyriakie Sarafoglou; Gregory P Forlenza; O Yaw Addo; Jennifer Kyllo; Aida Lteif; P C Hindmarsh; Anna Petryk; Maria Teresa Gonzalez-Bolanos; Bradley S Miller; William Thomas
Journal:  Clin Endocrinol (Oxf)       Date:  2017-03-28       Impact factor: 3.478

2.  Clinical guidelines for the diagnosis and treatment of 21-hydroxylase deficiency (2021 revision).

Authors:  Tomohiro Ishii; Kenichi Kashimada; Naoko Amano; Kei Takasawa; Akari Nakamura-Utsunomiya; Shuichi Yatsuga; Tokuo Mukai; Shinobu Ida; Mitsuhisa Isobe; Masaru Fukushi; Hiroyuki Satoh; Kaoru Yoshino; Michio Otsuki; Takuyuki Katabami; Toshihiro Tajima
Journal:  Clin Pediatr Endocrinol       Date:  2022-04-10

3.  Two Siblings with the Same Severe Form of 21-Hydroxylase Deficiency But Different Growth and Menstrual Cycle Patterns.

Authors:  Mariarosaria Lang-Muritano; Karine Gerster; Susanna Sluka; Daniel Konrad
Journal:  Front Pediatr       Date:  2017-03-01       Impact factor: 3.418

Review 4.  Metabolic Perspectives for Non-classical Congenital Adrenal Hyperplasia With Relation to the Classical Form of the Disease.

Authors:  Djuro Macut; Vera Zdravković; Jelica Bjekić-Macut; George Mastorakos; Duarte Pignatelli
Journal:  Front Endocrinol (Lausanne)       Date:  2019-10-02       Impact factor: 5.555

5.  Clinical Patterns and Linear Growth in Children with Congenital Adrenal Hyperplasia, an 11-Year Experience.

Authors:  Adnan Al Shaikh; Yasser AlGhanmi; Saniah Awidah; Abdullah Bahha; Mohamed E Ahmed; Ashraf T Soliman
Journal:  Indian J Endocrinol Metab       Date:  2019 May-Jun

6.  Combined homozygous 21 hydroxylase with heterozygous P450 oxidoreductase mutation in a Saudi boy presented with hypertension.

Authors:  Aida Aljabri; Fatimah Alnaim; Yasin Alsaleh
Journal:  BMJ Case Rep       Date:  2020-09-29

7.  Manipulation of Hydrocortisone Tablets Leads to Iatrogenic Cushing Syndrome in a 6-Year-Old Girl With CAH.

Authors:  Heba Al-Rayess; Kristin Fleissner; Mu'taz Jaber; Richard C Brundage; Kyriakie Sarafoglou
Journal:  J Endocr Soc       Date:  2020-07-05

Review 8.  Caring for individuals with a difference of sex development (DSD): a Consensus Statement.

Authors:  Martine Cools; Anna Nordenström; Ralitsa Robeva; Joanne Hall; Puck Westerveld; Christa Flück; Birgit Köhler; Marta Berra; Alexander Springer; Katinka Schweizer; Vickie Pasterski
Journal:  Nat Rev Endocrinol       Date:  2018-07       Impact factor: 43.330

9.  Does fludrocortisone treatment cause hypomagnesemia in children with primary adrenal insufficiency?

Authors:  İbrahim Mert Erbaş; Selda Ayça Altincik; Gönül Çatli; Tolga Ünüvar; Bayram Özhan; Ayhan Abaci; Ahmet Anik
Journal:  Turk J Med Sci       Date:  2021-02-26       Impact factor: 0.973

10.  Bone Age Maturation and Growth Outcomes in Young Children with CAH Treated with Hydrocortisone Suspension.

Authors:  Heba Al-Rayess; O Yaw Addo; Elise Palzer; Mu'taz Jaber; Kristin Fleissner; James Hodges; Richard Brundage; Bradley S Miller; Kyriakie Sarafoglou
Journal:  J Endocr Soc       Date:  2021-12-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.